• Yoyi Digital

  Led · Series D · Aug 2022

  Yoyi Tech is an omnichannel intelligent marketing platform founded in 2007 that leverages its Advertising, Data and Marketing clouds together with big data and AI. The company provides products and services to help clients acquire new customers, improve customer experience and drive business growth through digital marketing transformation. It combines advertising, data and marketing capabilities to enable omnichannel marketing execution. Recently Yoyi Tech completed a USD20m D+ financing, strengthening its financial position. The company also acquired LinkFlow, which will operate independently as a subsidiary under Yoyi Tech Group. LinkFlow focuses on building the next generation of Customer Data Platform and Marketing Automation Platform, supporting Yoyi Tech's expansion in MarTech. Yoyi Media provides precision-targeted online advertising and marketing solutions, offering both impression-based and performance-based ad products. Its platform enables targeting based on age, profession, geographic location, income level, personal interests, behavior, time and location. The platform has been used by advertisers including Toyota, P&G, Dell, Microsoft, Adidas and Carlsberg. Following its Series B, the company plans to use capital to enhance its video and rich media advertising platform and to expand its sales force and marketing network. In conjunction with the financing, Ren Riley of Oak Investment Partners will join the company’s board of directors. Founded in 2007 by CEO Junfeng Liu, Yoyi Media maintains support centers in Beijing, Shanghai and Guangzhou. Yoyi Media offers a product suite that delivers highly targeted advertising and promotional materials based on individual viewer characteristics such as age, profession, location, income level and interests. The company’s platforms serve both advertisers and media publishers and count China’s top-ranked websites and global brands like Audi, China Merchants Bank, Intel, Microsoft and Nokia among its customers. Yoyi completed a Series A financing to accelerate its business strategy and further enhance its advertising and brand-building platforms. Management intends to use the funding to deliver additional functionality to marketers and capture a larger portion of China’s growing online advertising market. CEO Junfeng Liu said the new funding will allow Yoyi to expand its performance marketing solutions to help clients drive additional sales and revenue growth. The company focuses on precision targeting to improve campaign performance and monetization for publishers.

• Robocath

  Participated · Series C · Apr 2020

  Robocath, founded in 2009, designs, develops and commercializes robotic solutions to treat cardiovascular diseases. Its first robotic-assisted platform, R-One™, optimizes safety in coronary angioplasty and is compatible with market-leading devices and cath labs; it is currently available in Europe and Africa. The company is developing a second-generation robot to cover more PCI procedures and to begin peripheral and neurovascular applications. The €40m Series C financing will be used to expand sales and marketing for R-One™ and accelerate product development of the next-generation system. Robocath plans to enter the Asian market through a China-based joint venture with MicroPort that will include local manufacturing, consumable production and robot assembly. Both companies will also pursue R&D on long-distance 5G remote-control technologies and AI algorithms for robotic-assisted platforms. Robocath has more than 30 employees and is backed by investors including GO CAPITAL, NCI, Normandie Participations, M Capital, Supernova Invest, Caisse d’épargne, BNP Paribas, Crédit Agricole and Bpifrance. Robocath develops robotic systems for the treatment of cardiovascular diseases, with a focus on robotic-assisted coronary procedures. Its first product, R-One™, is designed to optimize the safety of robotic-assisted coronary angioplasty. R-One™ received CE marking in February 2019. The company intends to use new funding to roll out its robotic platform in strategic European target markets. Robocath was founded in 2009 and is based in Rouen, France. It is led by newly hired CEO Lucien Goffart alongside founder and president Philippe Bencteux. Robocath develops R-One™, a robotic platform that optimizes and increases the safety of robotic-assisted coronary angioplasty by enabling precise operation from a seated position and using a portable X-ray protective screen. The company plans to market its first robotic platform in Europe and the Middle East in 2018 and will use new funding to increase resources for marketing R-One. Robocath will also launch development of a next-generation robotic platform targeted at neurovascular diseases such as strokes. The company received an additional €1.7M in funding which supplements a €4.7M close in May. Founded in 2009 by Philippe Bencteux, Robocath employs close to 20 staff. The funds are explicitly earmarked for commercialization of R-One and R&D on the next-generation stroke treatment robotics. Robocath designs and develops robotic solutions for the treatment of cardiovascular diseases, with its first platform, the R-one™, aimed at interventional cardiology. The integrated R-one platform is covered by 20 families of international patents and allows physicians to remotely manage instruments from a control panel close to the operating table. R-one incorporates two core technologies—R-grasp®, which reproduces hand movements including rotation and simultaneous movement, and SecurAccess®, which provides stability and security during procedures. The company is currently at the manufacturing stage and is in the process of obtaining the CE mark. Robocath intends to use the new funds for continued development and employs around 20 staff. Founded in 2009 in Rouen, France, the company previously raised €1.8m in 2013 and 2015 and received about €1.6m in public aid from Bpifrance and others.

• CMR Surgical

  Participated · Series C · Sep 2019

  CMR Surgical is a global medical devices company headquartered in Cambridge, United Kingdom, that develops the Versius Surgical Robotic System, a soft-tissue surgical robot for minimal access procedures. Its core product, Versius, is described as a versatile, adaptable, next-generation digitally driven surgical robot and was recently granted FDA marketing authorization for use in cholecystectomy. The company says it collaborates with surgical teams and hospital partners to make robotic minimal access surgery more accessible and affordable. Founded in 2014, CMR is a private limited company backed by an international shareholder base. Management plans to scale operations and accelerate commercial expansion, with a major focus on launching Versius in the United States. Financially, CMR recently closed a financing round of more than $200 million. CMR Surgical develops the Versius® surgical robotic system and is led by CEO Supratim Bose. The system gained CE approval in 2019 and more than 140 systems have been installed in hospitals worldwide. Versius has been used to perform more than 15,000 procedures across seven surgical specialties and over 130 procedure types. Installations span the UK, Europe, Latin America, the Middle East, Asia and Africa and include major research hospitals. The company intends to use the new funding for continued product innovation, new technological developments, and further commercialisation in key existing and new geographies. CMR Surgical develops Versius, a next-generation, portable and modular surgical robotic system designed for minimally invasive procedures. Versius reproduces natural human arm movement, offers 3D HD vision, fully articulated small instruments and an open surgeon console to improve ergonomics and team communication. The system is designed to fit into existing operating-room workflows and can be configured with only the number of arms required for a given procedure. CMR is building a digital ecosystem around Versius, including Versius Connect, Versius Trainer and a clinical registry to capture data for continuous learning. The company emphasizes affordability and global accessibility and has launched Versius in Europe, Australia, India and the Middle East. CMR was founded in 2014 and is headquartered in Cambridge, United Kingdom. CMR Surgical develops, manufactures and markets Versius, a modular surgical robotic system for minimal access surgery that offers 3D HD vision, instrument control and ergonomic working positions. Versius is designed to biomimic the human arm, providing surgeons with enhanced dexterity and precision. The company received the European CE Mark for the system in March 2019 and now has offices on four continents. CMR Surgical employs around 400 people and is led by CEO Martin Frost. The company intends to use new funding to scale global deliveries of Versius while supporting continued R&D, manufacturing and expansion. The business is actively commercializing its system to hospitals worldwide. CMR Surgical is developing a universal robotic system called Versius for minimal access surgery, intended for use across a range of surgical specialties. Led by CEO Martin Frost, the company is conducting preclinical trials that demonstrate Versius can perform upper gastrointestinal, gynaecological, colorectal and renal surgery. CMR will use the Series B proceeds to prepare the Versius system for planned commercialisation. Planned activities include completion of validation studies to support regulatory approval processes in Europe and the USA. The company also intends to fund international expansion and commercial scale-up. The company is based in Cambridge, UK.

No current team members are available.